MEDICA treatment resulted in decrease in tumor number, weight, and volume (Fig. 1a); loss of ErbB1, ErbB2, and ErbB3 in breast tumors (Fig. 1b); and decrease in lung metastatic neu cells (Fig. 1c). This evidence concerns the gene ERBB3 and breast neoplasm.